Skip to content. | Skip to navigation

Garvan Institute

Sections
 

Dr Daniel Christ

 

Senior Research Fellow; Group Leader Immunology Program and Director Antibody Development, Garvan Institute of Medical Research; Conjoint Senior Lecturer Faculty of Medicine, The University of New South Wales

Email: d.christ "at"garvan.org.au
Research Group: Antibody Engineering

 
 
Throughout his career Daniel has worked at the interface between the biological sciences and biotechnology. His work has led to important contributions in the field of monoclonal antibody technology and in-vitro evolution.
 
 
 

After undergraduate studies in Switzerland, Daniel joined Sir Gregory Winter's laboratory at Cambridge University for his PhD. Winter had shown that in-vitro evolution technology (such as phage display) can be used for the generation of therapeutic antibodies, initiating a multi-billion dollar biotechnology industry. At Cambridge, Christ and Winter further developed monoclonal antibody technology, particularly in the field of domain antibodies. He was elected a Fellow of Trinity College (Cambridge University) at age 29. He maintains close links with industry and was involved the foundation of Domantis Ltd, for which he worked as a consultant until its sale to GSK in 2006. Daniel joined Garvan in 2007 to head the newly established antibody engineering lab.

 

Education

2003 PhD, Cambridge University
1999 Dipl. Natw. (M.Sc.), Swiss Federal Institute of Technology (ETH)

Awards and Honours

2009 NHMRC CDA Fellow
2002 Fellow, Trinity College, Cambridge University
1999 ERS PhD Scholarship, Trinity College, Cambridge University
1999 Studer Prize (best graduate), Swiss Federal Institute of Technology (ETH)

Selected Publications

Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L and Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011;84:1-206

O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, Schofield P, McLeod D, Cooper CL, McNeil CM, McFarland A, Nguyen A, Ormandy CJ, Qiu MR, Rabinovich B, Martelotto LG, Vu D, Hannigan GE, Musgrove EA, Christ D, Sutherland RL, Watkins DN, Swarbrick A. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res 2011 71(11):4002-4014

McGuire H, Walters S, Vogelzang A, Lee CM, Webster KE, Sprent J, Christ D, Grey ST & King C. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 2010; 60(3):867-75.

Lee CM, McGuire H, King C & Christ D. Expression, purification and characterization of recombinant interleukin-21 J. Immunol. Methods 2010; 362 (1-2):185-189.

Dudgeon K, Famm K, Christ D. Sequence determinants of protein aggregation in human VH domains. Protein Eng Des Sel 2009; 22(3):217-220.

Famm K, Hansen L, Christ D & Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol 2008; 376:926-931.

Lee CM, Iorno N, Sierro F & Christ D. Selection of human antibody fragments by phage display. Nat Protoc 2007; 2(11):3001-3008

Christ D, Famm K, Winter G. Repertoires of aggregation-resistant human antibody domains. Protein Eng Des Sel 2007; 20(8):413-416.

Christ D, Famm K, Winter G. Tapping diversity lost in transformation - in vitro amplification of ligation reactions. Nucl Acids Res 2007; 34(16):e108.

Christ D, Winter G. Identification of protein domains by shotgun proteolysis. J Mol Biol 2006; 358(2):364-371.

Christ D, Winter G. Identification of functional similarities between proteins by directed evolution. Proc Natl Acad Sci U S A 2003; 100(23):13202-13206.

Search for all publications by D Christ

 
 
 

Areas of Interest

biologics, antibody therapeutics, phage display, protein engineering
 

News

 

Romain Rouet wins 2011 Castle Harlan Award

09 Nov 2011
Romain Rouet has received the $10,000 USD Castle Harlan Award for being the most outstanding early career PhD student at the Garvan Institute in 2011. Castle Harlan Inc. is a US-based private equity firm that wishes to support the kind of medical research being undertaken at Garvan.
 
 

Silencing a deadly conversation in breast cancer

MEDIA RELEASE: 02 Jun 2011
Garvan researchers have shown that a molecule known as ‘hedgehog’ sits at the centre of a cellular 'switchboard' in breast cancer, transmitting biochemical signals between the cancer cells and the healthy cells nearby. They have identified a new way of turning off this cellular cross talk - which would otherwise allow the cancer to thrive. This off switch offers a potential therapeutic, especially for women with cancers that do not respond to current treatments.
 
 

Geoffrey Grigg Travelling Fellowship between Garvan and the MRC Laboratory of Molecular Biology

02 Jun 2010
Garvan and the Medical Research Council's Laboratory of Molecular Biology (LMB), based in Cambridge, have set up the Geoffrey Grigg Travelling Fellowship aimed at enabling short scientific exchange visits between the two institutions.
 
 

Personal tools